DEFA14A: OptiNose to be Acquired by Paratek Pharmaceuticals in $330 Million Deal

OptiNose and Paratek Pharmaceuticals have entered into a merger agreement where Paratek will acquire OptiNose for a potential value of $330 million, pending shareholder approval and customary closing conditions.

Summary

• OptiNose has announced a merger agreement with Paratek Pharmaceuticals, where Paratek will acquire OptiNose.
• The deal has a potential value of approximately $330 million, including up to $14 per share for OptiNose shareholders.
• The consideration includes $9 per share in cash and up to $5 per share in Contingent Value Rights (CVRs) based on future XHANCE net sales milestones.
• The transaction is expected to close in mid-2025, subject to OptiNose shareholder approval and other customary conditions.
• Paratek aims to broaden awareness of XHANCE by leveraging its primary care sales force, which currently promotes NUZYRA.
• Paratek will pay $1 per share if XHANCE achieves $150M in net sales in any calendar year prior to December 31, 2028, and $4 per share if XHANCE achieves $225M in net sales in any calendar year prior to December 31, 2029.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook regarding the acquisition, highlighting the potential benefits for both companies and shareholders. The deal offers a premium for OptiNose shareholders and expands the market reach for XHANCE. However, there are inherent risks and uncertainties associated with the transaction, which temper the overall sentiment.

Positives

• The acquisition offers OptiNose shareholders a significant premium over the current trading price.
• The deal provides an opportunity to expand the reach of XHANCE to more healthcare professionals and patients through Paratek's primary care presence.
• The CVR structure aligns the interests of both companies in achieving future success with XHANCE sales.
• Paratek's existing infrastructure and sales force can potentially accelerate the growth of XHANCE.

Negatives

• The deal is subject to shareholder approval and customary closing conditions, which introduces uncertainty.
• The full potential value of $14 per share is contingent on achieving specific XHANCE net sales milestones, which may not be guaranteed.
• There is a risk of disruption from the pending merger, which could affect business and operational relationships.
• The announcement of the merger could negatively affect the market price of OptiNose's common stock.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Failure to obtain necessary regulatory approvals or shareholder approval could prevent the merger.
• The occurrence of any event that could lead to the termination of the merger agreement.
• Risks related to achieving the milestones necessary for the payment of any contingent value rights.
• Disruption from the pending merger may make it more difficult to maintain business and operational relationships.
• The merger could divert management's attention from ongoing business operations.
• There is a risk of litigation, including shareholder litigation, related to the merger.

Future Outlook

The transaction is expected to close in mid-2025, pending shareholder approval and customary closing conditions. Paratek plans to integrate OptiNose and leverage its primary care sales force to expand the reach of XHANCE.

Management Comments

• We are enthusiastic about the potential opportunity this planned acquisition represents to maximize the XHANCE growth opportunity and to help more patients improve their quality of life.
• The Paratek team truly respects and is enthusiastic about all that the people of Optinose have accomplished with XHANCE.
• Right now, the single most important thing for all of us at Optinose is the same as it was before the announcement to focus on successful achievement of our 2025 objectives.

Industry Context

This acquisition reflects a trend in the pharmaceutical industry where companies seek to expand their product portfolios and market reach through strategic mergers and acquisitions. Paratek's acquisition of OptiNose allows it to diversify its product offerings and leverage its existing sales infrastructure to promote XHANCE in the primary care market.

Comparison to Industry Standards

• Contingent Value Rights (CVRs) are a common construction in M&A transactions, and future sales milestones align our interests in aiming for future success with XHANCE.
• The structure of the deal, with a mix of cash and CVRs, is similar to other acquisitions in the pharmaceutical sector, such as Sanofi's acquisition of Bioverativ, which included CVRs based on the achievement of certain milestones.
• Paratek's strategy of leveraging its existing sales force to promote XHANCE is a common approach in the industry, similar to how Pfizer integrated Wyeth's products after their merger.

Stakeholder Impact

• Shareholders will receive cash and potential CVR payments.
• Employees face potential changes as a result of the integration, with severance benefits outlined.
• Customers and suppliers will be informed of the transaction, with talking points being developed.
• Patients may benefit from broader access to XHANCE through Paratek's primary care network.

Next Steps

• Optinose shareholders will vote on approval of the merger.
• A formal integration planning team will kick off to plan for closing and identify key issues.
• Paratek leadership will engage the Optinose team periodically in the weeks before closing.

Key Dates

Keywords

OptiNose, Paratek Pharmaceuticals, merger, acquisition, XHANCE, Contingent Value Rights, shareholders, net sales, primary care, pharmaceuticals